PathAI, GSK partner to accelerate research, drug development

2022 04 05 16 58 0661 Drug Discovery Development Analysis 400

PathAI and GlaxoSmithKline (GSK) have announced a strategic multiyear partnership to accelerate scientific research and drug development programs in oncology and non-alcoholic steatohepatitis (NASH).

Under the agreement, GSK will gain access to PathAI's technologies in digital pathology, including its artificial intelligence-based measurement of NASH (AIM-NASH) tool, which provides AI-based NASH scoring.

The companies said that the partnership will combine GSK's and PathAI's AI and platform engineering teams to scale algorithm development and enable the discovery of new insights that can be integrated into clinical trials.

Page 1 of 17
Next Page